Viatris (VTRS)
(Delayed Data from NSDQ)
$11.90 USD
0.00 (0.00%)
Updated Sep 19, 2024 03:59 PM ET
After-Market: $11.90 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$11.90 USD
0.00 (0.00%)
Updated Sep 19, 2024 03:59 PM ET
After-Market: $11.90 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth F Momentum C VGM
Zacks News
Do Options Traders Know Something About Viatris (VTRS) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Viatris (VTRS) stock based on the movements in the options market lately.
Icon PLC (ICLR) Surges 3.3%: Is This an Indication of Further Gains?
by Zacks Equity Research
Icon PLC (ICLR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Compared to Estimates, Viatris (VTRS) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Viatris (VTRS) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Viatris (VTRS) Q2 Earnings Outpace Estimates, Sales Miss
by Zacks Equity Research
Viatris' (VTRS) earnings beat estimates in the second quarter but sales miss the same. New products are performing well and the rise in annual guidance for these products' sales is encouraging.
Viatris (VTRS) Q2 Earnings Surpass Estimates
by Zacks Equity Research
Viatris (VTRS) delivered earnings and revenue surprises of 1.47% and 0.49%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
DocGo Inc. (DCGO) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Motion Acquisition (DCGO) delivered earnings and revenue surprises of -14.29% and 0.99%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Theravance (TBPH) Q2 Loss Wider Than Expected, Revenues Rise Y/Y
by Zacks Equity Research
Theravance (TBPH) misses second-quarter estimates on both fronts. Increased collaboration revenues from Viatris drive year-over-year top-line performance.
Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?
by Kanishka Das
Let's look at five biotech and drug companies, AMGN, GILD, LLY, VTRS & NVO, due to release their second-quarter 2024 results this week.
Seeking Clues to Viatris (VTRS) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Viatris (VTRS), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2024.
Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RSPH
Earnings Preview: Viatris (VTRS) Q2 Earnings Expected to Decline
by Zacks Equity Research
Viatris (VTRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Viatris (VTRS) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Viatris' (VTRS) Q2 results are likely to gain from growth in Emerging Markets and Europe and expansion of business activities in Japan, offset by declines in North America.
3 Generic Drug Stocks to Watch Amid Improving Market Prospects
by Sundeep Ganoria
With the ease in inflationary pressure, the Zacks Medical - Generic Drugs industry is expected to benefit from declining costs. New product launches provide some respite to AMPH, RDY, and TEVA.
Here's Why You May Invest in Theravance (TBPH) Stock Now
by Zacks Equity Research
Here, we discuss some reasons why investing in Theravance (TBPH) stock now may turn out to be a prudent move.
Theravance (TBPH) Q1 Earnings Top, Revenues Match Estimates
by Zacks Equity Research
Theravance's (TBPH) first-quarter 2024 earnings beat estimates while revenues meet the same.
Viatris' (VTRS) Q1 Earnings & Sales Lag Estimates, Stock Down
by Zacks Equity Research
Viatris (VTRS) Q1 numbers fall short of estimates. The company adjusts the annual guidance to reflect the impact of divestitures.
Viatris (VTRS) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Viatris (VTRS) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Viatris (VTRS) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Viatris (VTRS) delivered earnings and revenue surprises of -1.47% and 2.12%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for Viatris (VTRS)
by Zacks Equity Research
Viatris (VTRS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Watch These 5 Drug Stocks for Q1 Earnings: Beat or Miss?
by Kinjel Shah
Let us look at five drug, generic companies, PRGO, IOVA, VTRS, TEVA and ACAD, which are gearing up for their earnings release this week.
Viatris (VTRS) to Report Q1 Earnings: Is a Beat in Store?
by Zacks Equity Research
Viatris' (VTRS) Q1 results are likely to gain from momentum in its branded and incremental revenues from new product launches.
Viatris (VTRS) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates
by Zacks Equity Research
Evaluate the expected performance of Viatris (VTRS) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Viatris (VTRS) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Viatris (VTRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Icon PLC (ICLR) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Icon PLC (ICLR) delivered earnings and revenue surprises of 0.87% and 0.08%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Highlights Teva, Dr. Reddy's and Viatris
by Zacks Equity Research
Teva, Dr. Reddy's and Viatris have been highlighted in this Industry Outlook article.